CU23490B7 - Composición farmacéutica que contiene un inhibidor de histona desacetilasa - Google Patents

Composición farmacéutica que contiene un inhibidor de histona desacetilasa

Info

Publication number
CU23490B7
CU23490B7 CU20050237A CU20050237A CU23490B7 CU 23490 B7 CU23490 B7 CU 23490B7 CU 20050237 A CU20050237 A CU 20050237A CU 20050237 A CU20050237 A CU 20050237A CU 23490 B7 CU23490 B7 CU 23490B7
Authority
CU
Cuba
Prior art keywords
inhibitor
pharmaceutical composition
composition containing
histone
deacetilase
Prior art date
Application number
CU20050237A
Other languages
English (en)
Inventor
Yasuhiro Matsuba
Hideyuki Migita
Tatsuo Sugawara
Osamu Nakanishi
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CU23490B7 publication Critical patent/CU23490B7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un fármaco anticáncer que tiene un efecto sinérgico debido a la utilización combinada de un derivado de histona desacetilasa tal como la N-(2-aminofenil)-4-(N-(piridín-3-ilmetoxicarbonil)aminometil)benzamida (MS-275) y otra sustancia anticáncer activa.
CU20050237A 2003-05-26 2005-11-25 Composición farmacéutica que contiene un inhibidor de histona desacetilasa CU23490B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26

Publications (1)

Publication Number Publication Date
CU23490B7 true CU23490B7 (es) 2010-02-23

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050237A CU23490B7 (es) 2003-05-26 2005-11-25 Composición farmacéutica que contiene un inhibidor de histona desacetilasa

Country Status (27)

Country Link
US (1) US20070098816A1 (es)
EP (1) EP1626719A1 (es)
JP (1) JP2006526031A (es)
KR (1) KR100938712B1 (es)
CN (2) CN1794991A (es)
AR (1) AR045318A1 (es)
AU (1) AU2004241873C1 (es)
BR (1) BRPI0410959A (es)
CA (4) CA2634765A1 (es)
CL (1) CL2004001278A1 (es)
CO (1) CO5660262A2 (es)
CR (1) CR8163A (es)
CU (1) CU23490B7 (es)
EC (1) ECSP056253A (es)
IL (1) IL171941A0 (es)
ME (1) MEP32308A (es)
MX (1) MXPA05012345A (es)
NO (1) NO20055417L (es)
NZ (1) NZ543591A (es)
PE (1) PE20050206A1 (es)
RS (1) RS20050884A (es)
RU (1) RU2322971C2 (es)
TW (1) TW200505424A (es)
UA (1) UA81499C2 (es)
UY (1) UY28330A1 (es)
WO (1) WO2004103369A1 (es)
ZA (1) ZA200509515B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2425083T3 (es) 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006223086A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
CA2937005A1 (en) 2005-03-22 2006-09-28 President And Fellows Of Harvard College Treatment of protein degradation disorders
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2009501236A (ja) 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP5409015B2 (ja) * 2006-02-14 2014-02-05 プレジデント アンド フェロウズ オブ ハーバード カレッジ ヒストンデアセチラーゼ阻害剤
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
US8304451B2 (en) 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
SI2099442T1 (sl) * 2006-12-26 2015-03-31 Pharmacyclics, Inc. Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CN101970399A (zh) * 2007-12-14 2011-02-09 乔治敦大学 组蛋白脱乙酰酶抑制剂
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
EP2350005B1 (en) * 2008-08-29 2011-12-21 Bayer Pharma Aktiengesellschaft N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
MX2011006503A (es) 2008-12-19 2011-09-06 Vertex Pharma Derivados de pirazina utiles como inhibidores de la cinasa de atr.
WO2010093561A1 (en) * 2009-02-11 2010-08-19 Liangping Yu Particulate composition and the method of making the same
JP2012525371A (ja) * 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
NZ596863A (en) * 2009-06-08 2014-02-28 Gilead Sciences Inc Alkanoylamino benzamide aniline hdac inhibitor compounds
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
NZ598588A (en) * 2009-08-25 2014-05-30 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
EP2569313A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
KR102184246B1 (ko) 2011-09-30 2020-12-01 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물의 제조 방법
ES2940121T3 (es) 2011-09-30 2023-05-03 Vertex Pharma Tratamiento de cáncer de pulmón de células no pequeñas con inhibidores de ATR
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
DK2833973T3 (en) 2012-04-05 2018-01-02 Vertex Pharma Compounds useful as ATR kinase inhibitors and combination therapies thereof
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
SG11201702119PA (en) 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
JP7187308B2 (ja) 2015-09-30 2022-12-12 バーテックス ファーマシューティカルズ インコーポレイテッド Ｄｎａ損傷剤とａｔｒ阻害剤との組み合わせを使用する、がんを処置するための方法
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
HUP0103640A3 (en) * 1998-09-25 2003-01-28 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
DE60045890D1 (de) * 1999-04-27 2011-06-09 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
WO2001034131A2 (en) * 1999-11-10 2001-05-17 Warner-Lambert Company Combination chemotherapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
US20070098816A1 (en) 2007-05-03
KR20060009371A (ko) 2006-01-31
CA2634709A1 (en) 2004-12-02
KR100938712B1 (ko) 2010-01-25
RU2322971C2 (ru) 2008-04-27
CN101322707A (zh) 2008-12-17
TW200505424A (en) 2005-02-16
JP2006526031A (ja) 2006-11-16
PE20050206A1 (es) 2005-03-26
CA2634766A1 (en) 2004-12-02
RU2005140570A (ru) 2006-06-10
AU2004241873B2 (en) 2008-05-08
EP1626719A1 (en) 2006-02-22
NO20055417L (no) 2005-12-19
RS20050884A (sr) 2008-04-04
NZ543591A (en) 2009-09-25
IL171941A0 (en) 2006-04-10
UY28330A1 (es) 2004-12-31
ECSP056253A (es) 2006-10-25
CA2527191A1 (en) 2004-12-02
MXPA05012345A (es) 2006-02-08
NO20055417D0 (no) 2005-11-16
CR8163A (es) 2006-07-14
AR045318A1 (es) 2005-10-26
ZA200509515B (en) 2006-07-26
CA2634765A1 (en) 2004-12-02
UA81499C2 (en) 2008-01-10
AU2004241873B8 (en) 2008-05-29
BRPI0410959A (pt) 2006-07-04
MEP32308A (en) 2010-10-10
AU2004241873C1 (en) 2009-01-22
CL2004001278A1 (es) 2005-05-06
AU2004241873A1 (en) 2004-12-02
CO5660262A2 (es) 2006-07-31
WO2004103369A1 (en) 2004-12-02
CN1794991A (zh) 2006-06-28

Similar Documents

Publication Publication Date Title
CU23490B7 (es) Composición farmacéutica que contiene un inhibidor de histona desacetilasa
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
BRPI0414581A (pt) derivados de benzimidazol: preparação e aplicações farmacêuticas
TW200510375A (en) New compounds
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
NO20090175L (no) Stabile laquinimod sammensetninger
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
EA200801243A1 (ru) Фармацевтическое применение замещенных амидов
CL2003002611A1 (es) Compuestos derivados del acido tiofeno hidroxamico, 2-hidroxamida-5-[(aril o heteroaril)-disutituido-metil]-amida del acido tiofeno-2,5-dicarboxilico enantiomeros, composicion farmaceutica, procedimiento de preparacion, y su uso para el tratamiento d
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA200801997A1 (ru) Новые соединения
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
EA200300334A1 (ru) Новая соль периндоприла и содержащие ее фармацевтические композиции
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα
GB2427405A (en) Novel hydroxamates as therapeutic agents
CL2009001150A1 (es) Compuestos derivados de n-(2-amino-fenil)-acrilamidas, inhibidor de la histona-desacetilasa (hdac); procedimiento de preparacion; composicion faramceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
MXPA02010828A (es) Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)